Hovione Appoints Filipe Gaspar, PhD as Vice President R&D
Hovione has appointed Dr Filipe Gaspar as Vice President of its R&D organization. Dr Gaspar will lead teams based in Lisbon and New Jersey that serve the company's clients’ drug development projects; he will also be defining long-term product development strategies and collaborations. He will report to Guy Villax, Hovione’s Chief Executive.
“We are very pleased to have Filipe running our R&D. Filipe brings great science and leadership skills. For the last 10 years Filipe has been the driving force behind our particle engineering, and if we have four new drugs today on the market it is because he and his team made sure we had the right capabilities, knowhow and ability to deliver” said Guy Villax.
“I am honored to have the opportunity to lead this talented R&D team and help fulfilling our mission of serving our customers developing and delivering innovative medicines for patients”, said Filipe Gaspar.
Dr Gaspar is the co-author and co-inventor of numerous publications, scientific presentations and patents. He is a chemical engineer from Instituto Superior Técnico (Lisbon) and has a PhD in Chemical Engineering from the University of Birmingham.
Dr Gaspar joined Hovione in 2003 as a manufacturing engineer and later became responsible for the technical leadership of spray drying technology. In 2004, Dr Gaspar moved to R&D to start the Particle Engineering group, there he was involved in more than 120 projects from preclinical stage to commercial. During that period he was the Lead Scientist in four projects that reached commercial stage, including the first at Hovione submitted under Quality by Design. He was instrumental in many of the projects that contribute to Hovione’s growing success in Particle Engineering. In 2012 he moved to a Business Development role and spent a year based in New Jersey.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.